News & Analysis on Clinical Trial Services & Contract Research And Development
In the second part of a special report, In-PharmaTechnologist has taken a closer look at the Pharmaceutical Fine Chemicals Business of Clariant, which made a series of announcements on new investments in facilities in Europe and the US as well as new...
A European parliament vote on the REACH chemicals legislation last week struck a balance between health, the environment and industry after months of intense debate.
Avecia spin-off, Reaxa, has announced that Umicore has taken a 21 per cent stake in a move that underlines Reaxa's business strategy in looking at joint R&D, new product development and toll manufacturing agreements.
Solvias debuted its new 80-member ligand kit at CPhI 2005, offering manufacturers increased flexibility in active pharmaceutical ingredient (API) development and manufacturing.
Superfos has reported positive third quarter results after a troubled start to the year. The company attributes the turnaround to declining raw material prices and growth in European business sales.